ArticleApplied biochemistry and biotechnology2026
Ophiocordyceps indica from the Indian Himalayas Ameliorates the IgA Nephropathy in Mice.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Immunoglobulin A nephropathy (IgAN) is the most common form of chronic glomerulonephritis and a major cause of end-stage renal disease worldwide, currently lacks safe, effective therapies. Ophiocordyceps sinensis, a well-known traditional medicinal fungus and used for treating kidney-related disorders. In this study, we report for the first time the nephroprotective potential of Ophiocordyceps indica Gireesh Nadda & Aakriti Sharma 2023, a newly described entomopathogenic fungus isolated from the Indian Himalayas, against IgAN. UPLC-based metabolomic profiling of O. indica confirmed the presence of key nucleosides, including adenosine and cordycepin, exhibiting a profile comparable to O. sinensis. In vitro, O. indica extract significantly reduced oxidative stress and inflammatory markers in SV40-MES13 mesangial cells without inducing cytotoxicity. In vivo, oral administration of the extract to IgAN-induced mice improved renal function by reducing serum creatinine, urea, and urine microalbumin levels, while restoring body and kidney weights. The extract also significantly reduced pro-inflammatory cytokines (TNFα, IL6, IL18) and galactose-deficient IgA1 levels. Histological and molecular analyses revealed amelioration of glomerular hypertrophy and tubular degeneration, along with downregulation of fibrotic and kidney injury markers (TGFβ, αSMA, Nephrin, WT1, VEGF, Desmin). The nephroprotective and anti-inflammatory effects of O. indica were comparable to those of O. sinensis and dexamethasone. Our findings highlight the potent anti-inflammatory and nephroprotective properties of O. indica, supporting its potential as a novel therapeutic agent for managing IgAN.
Indexed as
Identifiers
41779330What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.